This summer, FluoroPharma Medical Inc., which is one of the portfolio companies managed by OmniView Capital with AJ Discala, released a company overview. The overview was presented by FluoroPharma’s President, CEO and Chairman of the Board, Thijs Spoor.
The point of the “State of the Union” as Thijs Spoor explained it was to provide shareholders with a perspective about the company and its evolution. It was intended, as well, to highlight the future potential that the company has.
As he said,
“Our pipeline is moving forward and we have further strengthened and expanded our global patent position. We believe that imaging agents like our BFPET and CardioPET, will provide Cardiologists around the world with faster, more accurate diagnostic tools with increased sensitivity for the detection and assessment of acute and chronic coronary artery disease (CAD). CAD affects millions of patients worldwide and cardiovascular diseases remain a leading cause of death and disability in the world.
On the capital markets side, we have expanded our presence and outreach in the investment community, and are making progress in raising our visibility with other key groups; including the medical community and industry media. I am pleased and proud to share with you that we are making significant strides in this area. This week, FluoroPharma was prominently featured in the prestigious Diagnostic & Interventional Cardiology Magazine in an article by the editor on advances in cardiac nuclear imaging. The article ‘PET vs. SPECT, Will PET Dominate over the Next Decade?’ clearly positions our company as an emerging leader as it addressed the advancements in new radiotracers and technology related to both modalities. Diagnostic & Interventional Cardiology Magazine is a publication of choice in our industry as it helps keep readers up to date on latest devices and technologies related to the catheterization laboratory, cardiac imaging, diagnostic testing and electrophysiology. In addition to new product releases, the magazine also reviews new technologies with clinician end-users, discusses trends, and offers product comparison charts. The full article can be found on our website or by following the URL http://www.dicardiology.com/article/pet-vs-spect-%E2%80%94-will-pet-dominate-over-next-decade.”
He continued, sharing a great deal of information, all of which can be read and accessed here: http://ir.stockpr.com/fluoropharma/company-news/detail/364/fluoropharma-ceo-provides-shareholders-with-a-state-of-the-union-communication.